000301518 001__ 301518
000301518 005__ 20250525020827.0
000301518 0247_ $$2doi$$a10.1186/s12885-025-14293-8
000301518 0247_ $$2pmid$$apmid:40399815
000301518 0247_ $$2altmetric$$aaltmetric:177316415
000301518 037__ $$aDKFZ-2025-01055
000301518 041__ $$aEnglish
000301518 082__ $$a610
000301518 1001_ $$0P:(DE-HGF)0$$aSprave, Tanja$$b0
000301518 245__ $$aDoes severe mucositis impair oncological outcome in head and neck cancer patients? A pooled analysis of two prospective studies with long-term follow-up.
000301518 260__ $$aLondon$$bBioMed Central$$c2025
000301518 3367_ $$2DRIVER$$aarticle
000301518 3367_ $$2DataCite$$aOutput Types/Journal article
000301518 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747989033_2829
000301518 3367_ $$2BibTeX$$aARTICLE
000301518 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301518 3367_ $$00$$2EndNote$$aJournal Article
000301518 520__ $$aOral mucositis (OM) is a frequently reported radiotherapy (RT)-induced acute toxicity in head and neck (H&N) cancer patients. Severe OM may be a dose-limiting condition, which can affect oncological outcomes. Therefore, we conducted a pooled analysis of two prospective studies with long-term follow-up to evaluate the impact of grade ≥3 OM on outcomes.This pooled analysis included 253 H&N cancer patients who received primary definitive or adjuvant chemoradiotherapy at the University of Freiburg Medical Center. Kaplan-Meier analyses with log-rank tests stratified for the presence of grade 3 OM were performed for overall survival (OS), local recurrence-free survival (LRFS), and distant-metastasis free survival (DMFS). Univariate Cox proportional hazards regression was performed to identify prognostic factors for OS, LRFS, and DMFS.The majority of participants had locally advanced disease: UICC stage IVA in 157 (62.1%) and IVB in 31 (12.3%). During treatment, 168 (66.4%) participants developed grade 3 OM. After a median follow-up of 73.6 months, the median OS was 64.6 months (95% CI, 47.6-83.7), and the median LRFS and DMFS had not yet been reached. Advanced disease stages had a significant impact on OS as follows: UICC IVb vs. I, HR 4.62 (95%-CI: 1.364-5.637, SE 0.6, p = 0.014) and UICC IVc vs. I, HR 9.01 (95%-CI: 1.500-54.1643, SE = 0.9, p = 0.016). Previous surgery also has a significant impact on OS with an HR 0.65 (95% CI: 0.440-0.948, SE 0.2, p = 0.026). RT duration also showed a significant impact on OS with HR 1.03 (95% CI: 1.002-1.067, SE = 0, p = 0.040). For LRFS, prior surgery had a significant impact with an HR of 0.46 (95% CI: 0.247-0.857, SE 0.3, p = 0.014). Furthermore, the cumulative RT dose had a measurable impact on LRFS with HR 1.10 (95% CI: 1.022-1.189, SE = 0.03, p = 0.012). Smoker status showed a significant effect on DMFS with an HR 3.29 (95% CI: 1.090-9.872, SE 0.561, p = 0.034). The presence of grade 3 OM has no significant impact on LRFS, OS, or DMFS.Severe acute grade 3 OM shows no long-term impact on oncological endpoints. Validation in larger multicenter cohorts is recommended.
000301518 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000301518 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301518 650_7 $$2Other$$aHead and neck cancer
000301518 650_7 $$2Other$$aMucositis
000301518 650_7 $$2Other$$aRadiation therapy
000301518 650_2 $$2MeSH$$aHumans
000301518 650_2 $$2MeSH$$aHead and Neck Neoplasms: therapy
000301518 650_2 $$2MeSH$$aHead and Neck Neoplasms: mortality
000301518 650_2 $$2MeSH$$aHead and Neck Neoplasms: pathology
000301518 650_2 $$2MeSH$$aHead and Neck Neoplasms: complications
000301518 650_2 $$2MeSH$$aMale
000301518 650_2 $$2MeSH$$aMiddle Aged
000301518 650_2 $$2MeSH$$aFemale
000301518 650_2 $$2MeSH$$aAged
000301518 650_2 $$2MeSH$$aProspective Studies
000301518 650_2 $$2MeSH$$aFollow-Up Studies
000301518 650_2 $$2MeSH$$aStomatitis: etiology
000301518 650_2 $$2MeSH$$aStomatitis: pathology
000301518 650_2 $$2MeSH$$aAdult
000301518 650_2 $$2MeSH$$aTreatment Outcome
000301518 650_2 $$2MeSH$$aPrognosis
000301518 650_2 $$2MeSH$$aAged, 80 and over
000301518 650_2 $$2MeSH$$aChemoradiotherapy: adverse effects
000301518 650_2 $$2MeSH$$aNeoplasm Staging
000301518 650_2 $$2MeSH$$aMucositis: etiology
000301518 650_2 $$2MeSH$$aKaplan-Meier Estimate
000301518 7001_ $$aSahlmann, Jörg$$b1
000301518 7001_ $$0P:(DE-HGF)0$$aThomsen, Andreas R$$b2
000301518 7001_ $$aKlein, Diana$$b3
000301518 7001_ $$0P:(DE-HGF)0$$aSchäfer, Henning$$b4
000301518 7001_ $$0P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aStoian, Raluca$$b5
000301518 7001_ $$aVerma, Vivek$$b6
000301518 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b7
000301518 7001_ $$0P:(DE-HGF)0$$aOrdonez, Elsa Beatriz Monroy$$b8
000301518 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-025-14293-8$$gVol. 25, no. 1, p. 909$$n1$$p909$$tBMC cancer$$v25$$x1471-2407$$y2025
000301518 909CO $$ooai:inrepo02.dkfz.de:301518$$pVDB
000301518 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000301518 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000301518 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000301518 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000301518 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000301518 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000301518 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000301518 9141_ $$y2025
000301518 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:34:06Z
000301518 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:34:06Z
000301518 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-04-10T15:34:06Z
000301518 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-20
000301518 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-20
000301518 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK Koordinierungsstelle Freiburg$$x0
000301518 980__ $$ajournal
000301518 980__ $$aVDB
000301518 980__ $$aI:(DE-He78)FR01-20160331
000301518 980__ $$aUNRESTRICTED